6.67
-0.02(-0.30%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
420
First IPO Date
May 31, 2013
| Name | Title | Pay | Year Born |
| Mr. Amir London | Chief Executive Officer | 674,000 | 1969 |
| Mr. David Tsur | Co-Founder & Independent Deputy Chairman of the Board | 252,000 | 1950 |
| Mr. Jon R. Knight | Vice President of US Commercial Operations | 302,000 | 1966 |
| Mr. Boris Gorelik | Vice President of Business Development & Strategic Programs | 392,000 | 1982 |
| Mr. Eran Nir | Chief Operating Officer | 417,000 | 1973 |
| Mr. Chaime Orlev | Chief Financial Officer | 478,000 | 1970 |
| Ms. Hanni Neheman | Vice President of Marketing & Sales | 0 | 1970 |
| Ms. Liron Reshef | Vice President of Human Resources | 0 | 1972 |
| Ms. Shavit Beladev | Vice President of Kamada Plasma | 0 | N/A |
| Mr. Nir Livneh B.A., L.L.B. | Vice President, General Counsel & Corporate Secretary | 0 | 1980 |
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
